Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Biological and comorbidity factors outweigh lymph node metrics in predicting outcomes after small-bowel neuroendocrine tumour resection.

Surgical oncology·2026
Same author

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience.

Endocrine oncology (Bristol, England)·2026
Same author

Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial Collaboration.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Impact of Symptom Phenotype on Surgical Quality and Survival in Small-Bowel Neuroendocrine Tumours: A Quality Metrics Analysis.

Journal of surgical oncology·2026
Same author

Quantification, radiomics and artificial intelligence in infection imaging: Current status and future directions in nuclear medicine.

Seminars in nuclear medicine·2026
Same journal

SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [<sup>68</sup>Ga]Ga-DOTATOC and [<sup>68</sup>Ga]Ga-SSO120 with [<sup>18</sup>F]FDG PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Discovery of a Thermostable Nigerose Phosphorylase for the Efficient Chemoenzymatic Radiosynthesis of a <i>S. aureus</i>-Targeted <sup>18</sup>F-Disaccharide.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

End-to-End PET/CT Interpretation and Quantification with an LLM-Orchestrated AI Agent: A Real-World Pilot Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Renal Medullary Carcinoma: Utility of [<sup>18</sup>F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 25, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K

Not All Gatekeepers Are Theranostics

Dale L Bailey

    Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
    |June 29, 2023
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.1K
    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    11.5K

    Related Experiment Videos

    Last Updated: Jul 25, 2025

    Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
    10:47

    Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

    Published on: February 3, 2015

    8.8K
    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.1K
    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    11.5K